Nkarta (NASDAQ:NKTX) Price Target Cut to $10.00 by Analysts at Stifel Nicolaus

Nkarta (NASDAQ:NKTX) had its price objective trimmed by Stifel Nicolaus from $11.00 to $10.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

NKTX has been the topic of a number of other reports. Wall Street Zen upgraded Nkarta from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 2nd. TD Cowen started coverage on Nkarta in a research report on Tuesday, June 23rd. They set a “buy” rating for the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Nkarta in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Wednesday, June 24th. Finally, Evercore set a $9.00 target price on shares of Nkarta in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.20.

Nkarta Price Performance

Shares of NASDAQ:NKTX opened at $2.33 on Friday. The firm has a fifty day moving average price of $2.64 and a two-hundred day moving average price of $2.58. The company has a market cap of $166.87 million, a price-to-earnings ratio of -1.48 and a beta of 0.93. Nkarta has a one year low of $1.70 and a one year high of $3.72.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.18). Equities research analysts expect that Nkarta will post -1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NKTX. Abel Hall LLC purchased a new position in shares of Nkarta during the fourth quarter worth approximately $27,000. The Manufacturers Life Insurance Company purchased a new position in Nkarta in the 1st quarter worth $30,000. Pallas Capital Advisors LLC purchased a new position in Nkarta in the 2nd quarter worth $31,000. Dynamic Technology Lab Private Ltd bought a new stake in Nkarta in the fourth quarter worth $37,000. Finally, Canada Pension Plan Investment Board bought a new stake in Nkarta in the second quarter worth $81,000. 80.54% of the stock is currently owned by institutional investors.

Key Headlines Impacting Nkarta

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.